Loading clinical trials...
Loading clinical trials...
An Randomized, Three-treatment, Three-period, Three-sequence, Multiple Dose, Crossover, Comparative Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg In Normal, Healthy, Adult, Human Subjects Under Fed Conditions
Conditions
Interventions
Orlistat 60mg Cap
Locations
1
China
Shaohong Yin
Linyi, Shandong, China
Start Date
October 1, 2020
Primary Completion Date
March 1, 2021
Completion Date
March 31, 2021
Last Updated
October 13, 2021
NCT07345130
NCT06969963
NCT06924190
NCT06830954
NCT06758531
NCT06600282
Lead Sponsor
Shandong New Time Pharmaceutical Co., LTD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions